BioCentury | Oct 21, 2020
Product Development

Aducanumab looms larger after Biogen cuts guidance, shelves programs in MS and SMA

...it has submitted an MAA for aducanumab to EMA to treat Alzheimer’s disease. The anti-β amyloid...
BioCentury | Sep 29, 2020
Product Development

Alzheimer milestones & vaccine politics: a BioCentury podcast

...to treat Alzheimer’s. Koch says the timing of the meeting suggests a decision on the anti-amyloid...
BioCentury | Sep 29, 2020
Financial News

Sept. 28 Quick Takes: Biogen gains $1.4B on aducanumab update; plus Zai, XtalPi, InventisBio, Galecto, Innovent, Galapagos-Gilead, Biocytogen and ACT Accelerator

...committee meeting on Nov. 6 to discuss anti-amyloid...
BioCentury | Sep 25, 2020
Finance

Human genetics leading the pull of investors into neuro

...multiple lines of genetic evidence pointing to β amyloid...
BioCentury | Sep 24, 2020
Product Development

The road ahead for the tau hypothesis of Alzheimer’s disease

...behind amyloid (see “Is Tau the New Amyloid?”).Six...
...it reached in January 2019, after its anti-amyloid...
...it is for β-amyloid, though even with amyloid-targeting...
BioCentury | Sep 19, 2020
Translation in Brief

Gene therapies from Passage Bio, Locanabio; Lava’s antitumor bispecific, health disparities in Alzheimer’s and more

...of the Health and Aging Brain Among Latino Elders-Amyloid, Tau, and Neurodegeneration (HABLE-AT(N)) study to include amyloid...
BioCentury | Sep 15, 2020
Emerging Company Profile

Attralus debuts with $25M series A to tackle systemic amyloidosis

...multiple types of systemic amyloidosis. The company’s pan-amyloid molecules target motifs that are present on all amyloid...
...of the problem by reducing the amount of new amyloid formed. They’re not directly impacting amyloid...
...demonstrating that its imaging agent AT-01 binds multiple forms of amyloid. “We’re seeing presymptomatic cardiac amyloid...
BioCentury | Sep 10, 2020
Product Development

Master protocols should not be a one-off phenomenon confined to COVID-19

...far focused on the disease’s longest-standing target: amyloid. Other...
BioCentury | Sep 10, 2020
Product Development

Having touched the third rail of data sharing in the pandemic, drug developers should hold on tight

...targets – such as CD47, IL-17 or  β–amyloid...
BioCentury | Aug 27, 2020
Distillery Therapeutics

A collagen receptor as an Alzheimer’s target

...treat Alzheimer’s disease by reducing platelet-associate β amyloid...
...patients with GP6 deficiency exhibited less β amyloid...
...platelets from GP6 knockout mice induced less β amyloid...
Items per page:
1 - 10 of 1966